Literature DB >> 23133806

Molecular imaging of therapy response with (18)F-FLT and (18)F-FDG following cyclophosphamide and mTOR inhibition.

Marijke De Saint-Hubert1, Lieselot Brepoels, Ellen Devos, Peter Vermaelen, Tjibe De Groot, Thomas Tousseyn, Luc Mortelmans, Felix M Mottaghy.   

Abstract

PURPOSE: Evaluation and comparison of 3'-[(18)F]-fluoro-3'-deoxy-L-thymidine (FLT) and 2-[(18)F]-fluoro-2-deoxyglucose (FDG)-PET to monitor early response following both cyclophosphamide and temsirolimus treatment in a mouse model of Burkitt lymphoma.
METHODS: Daudi xenograft mice were treated with either cyclophosphamide or temsirolimus and imaged with FLT-PET and FDG-PET on appropriate days post therapy inititiation. Immunohistochemical (IHC) studies (H&E, TUNEL, CD20, PCNA and ki-67) and DNA flow cytometry studies were performed.
RESULTS: FDG tumor uptake decreased immediately after cyclophosphamide treatment while FLT-PET showed only a late and less pronounced decrease. A fast induction of apoptosis was observed together with an early accumulation of cells in the S-phase of the cell cycle, suggesting DNA repair. Temsirolimus treatment reduced both FDG and FLT tumor uptake immediately after therapy and resulted in a fast induction of apoptosis and G(0)-G(1) phase accumulation.
CONCLUSION: FLT response was less distinct than FDG response and may be controlled by DNA repair early after cyclophosphamide. Nevertheless, FLT-PET was able to reflect decreased proliferation following temsirolimus.

Entities:  

Keywords:  Burkitt lymphoma; FDG-PET; FLT-PET; cyclophosphamide; mTOR inhibition; therapy response

Year:  2011        PMID: 23133806      PMCID: PMC3478112     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  30 in total

Review 1.  [18F]FLT; portrait of a proliferation marker.

Authors:  W Mier; U Haberkorn; M Eisenhut
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-02       Impact factor: 9.236

Review 2.  [18F]FLT-PET in oncology: current status and opportunities.

Authors:  Lukas B Been; Albert J H Suurmeijer; David C P Cobben; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12       Impact factor: 9.236

Review 3.  Use of PET for monitoring cancer therapy and for predicting outcome.

Authors:  Wolfgang A Weber
Journal:  J Nucl Med       Date:  2005-06       Impact factor: 10.057

4.  Effect of corticosteroids on 18F-FDG uptake in tumor lesions after chemotherapy.

Authors:  Lieselot Brepoels; Sigrid Stroobants; Peter Vandenberghe; Karoline Spaepen; Patrick Dupont; Johan Nuyts; Guy Bormans; Luc Mortelmans; Gregor Verhoef; Christiane De Wolf-Peeters
Journal:  J Nucl Med       Date:  2007-03       Impact factor: 10.057

5.  [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction?

Authors:  Karoline Spaepen; Sigrid Stroobants; Patrick Dupont; Guy Bormans; Jan Balzarini; Gregor Verhoef; Luc Mortelmans; Peter Vandenberghe; Christine De Wolf-Peeters
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-25       Impact factor: 9.236

6.  Inhibition of Mammalian target of rapamycin by rapamycin causes the regression of carcinogen-induced skin tumor lesions.

Authors:  Panomwat Amornphimoltham; Kantima Leelahavanichkul; Alfredo Molinolo; Vyomesh Patel; J Silvio Gutkind
Journal:  Clin Cancer Res       Date:  2008-12-10       Impact factor: 12.531

7.  Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.

Authors:  Steven M. Larson; Yusuf Erdi; Timothy Akhurst; Madhu Mazumdar; Homer A. Macapinlac; Ronald D. Finn; Cecille Casilla; Melissa Fazzari; Neil Srivastava; Henry W.D. Yeung; John L. Humm; Jose Guillem; Robert Downey; Martin Karpeh; Alfred E. Cohen; Robert Ginsberg
Journal:  Clin Positron Imaging       Date:  1999-05

8.  Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model.

Authors:  Aren van Waarde; David C P Cobben; Albert J H Suurmeijer; Bram Maas; Willem Vaalburg; Erik F J de Vries; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga
Journal:  J Nucl Med       Date:  2004-04       Impact factor: 10.057

Review 9.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

10.  Early changes in [18F]FLT uptake after chemotherapy: an experimental study.

Authors:  Helmut Dittmann; Bernhard Matthias Dohmen; Rainer Kehlbach; Gabi Bartusek; Maren Pritzkow; Mario Sarbia; Roland Bares
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-09-06       Impact factor: 9.236

View more
  12 in total

Review 1.  Multimodality imaging of CXCR4 in cancer: current status towards clinical translation.

Authors:  T R Nayak; H Hong; Y Zhang; W Cai
Journal:  Curr Mol Med       Date:  2013-12       Impact factor: 2.222

Review 2.  Biomedical applications of zinc oxide nanomaterials.

Authors:  Y Zhang; T R Nayak; H Hong; W Cai
Journal:  Curr Mol Med       Date:  2013-12       Impact factor: 2.222

3.  Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET.

Authors:  Lars Stelter; Simon Fuchs; Achim A Jungbluth; Gerd Ritter; Valerie A Longo; Pat Zanzonico; Nathanael Raschzok; Igor M Sauer; John S Bomalaski; Steven M Larson
Journal:  Mol Imaging Biol       Date:  2013-12       Impact factor: 3.488

4.  Bioluminescence imaging of therapy response does not correlate with FDG-PET response in a mouse model of Burkitt lymphoma.

Authors:  Marijke De Saint-Hubert; Ellen Devos; Abdelilah Ibrahimi; Zeger Debyser; Luc Mortelmans; Felix M Mottaghy
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-07-10

Review 5.  Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies.

Authors:  Mette Munk Jensen; Andreas Kjaer
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-10-12

6.  18 F-fluorothymidine uptake in follicular lymphoma and error-prone DNA repair.

Authors:  Marielle J Wondergem; Ken Herrmann; Sergei Syrbu; Josée M Zijlstra; Nikie Hoetjes; Otto S Hoekstra; Saskia Agm Cillessen; Laura M Moesbergen; Andreas K Buck; Julie M Vose; Malik E Juweid
Journal:  EJNMMI Res       Date:  2014-01-08       Impact factor: 3.138

Review 7.  Positron emission tomography imaging of atherosclerosis.

Authors:  Hakan Orbay; Hao Hong; Yin Zhang; Weibo Cai
Journal:  Theranostics       Date:  2013-11-02       Impact factor: 11.556

8.  Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma.

Authors:  Nicolas Graf; Zhoulei Li; Ken Herrmann; Daniel Weh; Michaela Aichler; Jolanta Slawska; Axel Walch; Christian Peschel; Markus Schwaiger; Andreas K Buck; Tobias Dechow; Ulrich Keller
Journal:  Onco Targets Ther       Date:  2014-05-23       Impact factor: 4.147

9.  Tyrosine Kinase Inhibitors Reduce Glucose Uptake by Binding to an Exofacial Site on hGLUT-1: Influence on 18 F-FDG PET Uptake.

Authors:  Vijaya L Damaraju; Maral Aminpour; Michelle Kuzma; Philip Winter; Jordane Preto; Jack Tuszynski; Alexander B J McEwan; Michael B Sawyer
Journal:  Clin Transl Sci       Date:  2021-05-03       Impact factor: 4.689

10.  The chick chorioallantoic membrane as an in vivo xenograft model for Burkitt lymphoma.

Authors:  Marcel Klingenberg; Jürgen Becker; Sonja Eberth; Dieter Kube; Jörg Wilting
Journal:  BMC Cancer       Date:  2014-05-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.